SMC
PGEN icon

Smith, Moore & Co’s Precigen PGEN Stock Holding History

Smith, Moore & Co’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Hold
20,000
– – 0.01% 575
2026
Q1 		$77.4K Hold
20,000
– – 0.01% 551
2025
Q4 		$83.6K Hold
20,000
– – 0.01% 520
2025
Q3 		$65.8K Hold
20,000
– – 0.01% 520
2025
Q2 		$28.4K Hold
20,000
– – ﹤0.01% 512
2025
Q1 		$29.8K Hold
20,000
– – ﹤0.01% 480
2024
Q4 		$22.4K Buy
20,000
+5,000
+33% +$4.26K ﹤0.01% 480
2024
Q3 		$14.2K Buy
+15,000
New +$18.9K ﹤0.01% 467

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $3.05B AUM 42.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Smith, Moore & Co's PGEN Position: Q2 2026 in Review

Smith, Moore & Co held its Precigen (PGEN) position steady in Q2 2026 at 20,000 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #575.

Smith, Moore & Co first reported a position in PGEN in Q3 2024 and has held it in 8 quarters since. 211 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

  • Smith, Moore & Co held 20,000 shares of Precigen worth $114K as of Q2 2026.
  • Smith, Moore & Co left its Precigen share count unchanged in Q2 2026.
  • Precigen made up 0.01% of Smith, Moore & Co's portfolio in Q2 2026, its #575 holding.
  • Smith, Moore & Co first reported a position in Precigen in Q3 2024 and has held it in 8 quarters since.
  • 211 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on Smith, Moore & Co's 13F filing for Q2 2026, filed 12 Aug 2026.